Skip to main content
Article thumbnail
Location of Repository

Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management

By Matthew V Brumm and Quan Dong Nguyen

Abstract

Uveitis is a potentially sight-threatening inflammatory eye disease caused by multiple infectious and non-infectious etiologies for which the standard of care involves corticosteroids or various immunomodulary therapy (IMT) drugs. These available treatments, although effective, may cause significant morbidity and sometimes mortality in uveitis patients due to their toxic side-effects and the necessity of long-term therapy to prevent recurrences. In order to avoid the systemic toxicity of corticosteroids and IMT or the repeated injections of local steroids necessary to control ocular inflammation, and to prevent development of cumulative damage resulting from recurrent episodes of inflammation, researchers have developed a number of local corticosteroid sustained-release devices that can be implanted directly into the vitreous of the eye, at the site of the inflammatory disease. Preliminary studies of such a device, the fluocinolone acetonide (Retisert™) implant, have shown significant reductions in the number of inflammatory episodes and decreased reliance on systemic corticosteroids or other IMT. This review explores the current research evaluating the fluocinolone sustained-release intravitreal implant in the treatment of posterior uveitis and the implications for its future use on a wider scale

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2673825
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). Basic and clinical science course, section 9: intraocular infl ammation and uveitis. San Francisco: American Academy of Ophthalmology.
    2. (2004). Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial.
    3. (2000). Dexamethasone sustained drug delivery implant for the treatment of severe uveitis.
    4. (2002). Diagnosis and treatment of uveitis.
    5. (2006). Fluocinoline Acetonide Uveitis Study Group.
    6. (2000). Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.
    7. (2005). Glaucoma in patients with ocular inflammatory disease.
    8. (2005). Immunosuppression for posterior uveitis.
    9. (2004). Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study,
    10. (1995). Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis.
    11. (2005). Long-term follow-up results of a pilot trial of a fl uocinolone acetonide implant to treat posterior uveitis.
    12. (2000). Ocular complications of topical, peri-ocular, and systemic corticosteroids.
    13. (2004). Ocular pharmacokinetics of fl uocinolone acetonide after Retisert intravitreal implanation in rabbits over a 1-year period.
    14. (1999). Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant.
    15. (2005). Outcome of intravitreal triamcinolone in uveitis. Ophthalmology,
    16. (1999). Posterior sub-Tenon’s steroid injections for the treatment of posterior ocular infl ammation: indications, effi cacy and side effects. Graefes Arch Clin Exp Ophthalmol,
    17. (2000). Safety and pharmacokinetics of an intraocular fl uocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci,
    18. (1997). Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.
    19. (2000). Treatment strategies in patients with posterior uveitis.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.